AI-Powered IVF Excellence
To develop and deploy Garbha.ai, India's first AI-driven fertility care platform that transforms IVF outcomes by replacing manual, subjective embryo assessments with intelligent, standardized AI predictions - ultimately improving IVF success rates to 88%+ while reducing treatment costs by up to 50%.
Location: India (with planned expansion to ASEAN, UAE, and US markets)
B2LSPRY Private Limited
Live Product Demo
Click to play demonstration video
Experience our AI-powered embryo analysis in action
Manual, Subjective Assessments in IVF:
Current embryo assessments in IVF are manual, subjective, and inconsistent, limiting success rates. With rising global demand, there's an urgent need for accurate, standardized methods to improve outcomes, reduce patient stress, and lower costs.
Embryo Quality Assessment Solution:
AI-powered embryo quality assessment system that automates and standardizes evaluations, delivering consistent, accurate predictions to optimize IVF success rates, reduce variability and costs, and enhance patient satisfaction.
India: $1.45B (7.8% CAGR) | APAC: $9B | Global: $26B
IVD market: $395M USD projected to grow at CAGR of 4.6% from 2024 to 2030
The Indian IVF market is valued at USD 1.06 billion (2023) and is projected to grow at a 7.8% CAGR through 2030, driven by over 28 million infertile couples and low IVF success rates of 30-35% per treatment cycle. Globally, the IVF market is estimated at USD 25.3 billion and expanding rapidly as fertility technologies gain wider adoption.
Primary (B2B): IVF Clinics and Fertility Centers
Secondary (B2B2C): Patients through clinic partnerships
Tertiary (B2B): Pharma companies for drug efficacy studies
Technology Status: Market ready with continuous innovation
Commercial Launch: Expected Q2 2026 after CDSCO Manufacturing License
Aligned with: SDG 3 (Sustainable Development Goal - Good Health and Well-being), SDG 5 (Gender Equality), SDG 9 (Industry, Innovation and Infrastructure)
End-to-end AI assessment from gametes to embryo transfer - maximizing success at every stage
AI analyzes sperm motility, morphology, and concentration for optimal selection - improving fertilization rates by 40%.
Automated tracking of follicle growth and maturation timing - ensuring precise ovulation prediction and egg retrieval.
Real-time oocyte maturity and quality grading - selecting the best eggs for fertilization with 92% accuracy.
Multi-stage CNN analysis from Day 1 to Day 5 - standardizing embryo selection with 88% success prediction.
AI-powered endometrial receptivity analysis - identifying the optimal transfer window for maximum implantation success.
Personalized pharmacogenomics treatment - AI-guided hormone therapy recommendations to reduce trial-and-error.
Delivery Model: SaaS solution with EMR integration
Market: $1.45B India | $25.3B Global opportunity
Multi-stage CNN where each stage focuses on different aspects of embryo development (Day 1-5). First stage classifies basic morphological features, second stage analyzes blastocyst development, compaction, and time-lapse characteristics.
Shows how model predictions evolve over time using time-lapse imaging. Displays viability scores across stages in timeline format for transparent AI decisions.
Combines embryo image data with non-image data (maternal age, genetic testing, lab conditions). CNN processes images while MLP processes clinical data, combined in fusion layer for final classification.
Grad-CAM/LRP generates heatmaps highlighting embryo regions influencing decisions. Reveals key features like inner cell mass and blastomere symmetry driving viability predictions.
Model Building → Explainability → Clinical Insights
Status: Completed
Phygital Module: Completed
Dubai and Singapore: In Progress
250 clinic installation into their timelapse hardware: In Discussion